Sat, Jul 12, 2014, 2:58 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Lotus Pharmaceuticals, Inc. Message Board

  • blutribe27 blutribe27 Apr 20, 2010 1:30 PM Flag

    Breaking news!!!!!!!!!!!!!!!

    Lotus Pharmaceuticals' Innovative Drug to Receive SFDA Fast Track ApprovalLast update: 4/20/2010 1:22:00 PMBEIJING, April 20, 2010 /PRNewswire via COMTEX/ -- Lotus Pharmaceuticals, Inc. (LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC") reported that its asthma drug Laevo-Bambutero will receive the China's State Food & Drug Administration's (SFDA) Fast Track Approval to enter clinical trials. The SFDA's Drug Review and Evaluation Center told the Company during recent consultations at the end of the Company's IND (Investigative New Drug Application) that formal approval would be granted by the Beijing office of the SFDA. Laevo-Bambutero has completed the SFDA special review process under Category Two of the four categories of drugs that can receive speedier approval for IND, clinical trials and new drug production. SFDA issues special review and fast-track approval procedures for new drugs in 2009, under the following four categories of drugs:
    1) New active pharmaceutical ingredients (APIs) extracted from plants, animals or minerals, and newly discovered traditional Chinese medicines (TCM), along with their preparations, and products that are not sold in the domestic market; 2) Drugs, and their APIs, preparations, and biological products, have not been approved in the domestic and overseas market; 3) New drugs with superior efficacy for AIDS, malignant tumors and other rare diseases; and 4) New drugs for diseases for which there is no existing effective treatment.CEO, Dr. Zhongyi Liu, commented, "Millions of people are suffering from asthma worldwide

 
LTUS
0.0150.000(0.00%)Jul 11 9:30 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.